Superseded public profile

FDA-approved↗↗↗↗↗Endocrine↗

Superseded · version 3: Leuprolide↗

Related names recorded in this version: Leuprolide acetate, Lupron, Eligard, Vobrig↗↗↗↗

A GnRH agonist FDA-approved since 1985 under several names. The cited label covers palliative treatment of advanced prostate cancer; FDA approved Vobrig for central precocious puberty in August 2026.↗↗↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Update · November 14, 2026

We added a plain-language reader guide with cited answers, Drugs@FDA approval records for leuprolide products, FDA’s August 26, 2026 approval of Vobrig for central precocious puberty, and the HERO trial. DailyMed no longer serves the cited label version, so we checked it against the current rendering of the same label set. 127

What this version reported

The label describes a controlled comparison with another hormone treatment in prostate cancer, and leuprolide served as the comparison treatment in a large randomized trial. Each leuprolide product has its own label and uses.↗↗

Organizations named in cited records:
  • U.S. National Library of Medicine↗
  • U.S. Food and Drug Administration↗↗

Reader guide in this version

Key takeaway

Leuprolide is a lab-made version of gonadotropin-releasing hormone (GnRH) that, after an initial rise, suppresses the body’s production of testosterone and estrogen.1 It has been FDA-approved since 1985 and is sold under several names, including Lupron, Lupron Depot, Eligard and Fensolvi. The label cited here covers palliative treatment of advanced prostate cancer.1,2,3,5,6 On August 26, 2026, FDA approved another leuprolide product, Vobrig, for central precocious puberty in children.7

At a glance

What it is
A GnRH agonist. The label describes leuprolide acetate as a synthetic nonapeptide analogue of GnRH that is more potent than the natural hormone.1
FDA status
FDA-approved. Drugs@FDA lists Lupron with an original approval date of April 9, 1985, and many later leuprolide applications. The cited label has no boxed warning.1,2,3
Human evidence
A controlled comparison with another hormone treatment described in the label, and a large randomized trial in which leuprolide was the comparison treatment.1,8
Evidence strength
Large randomized human trials

What is leuprolide?

Leuprolide is a lab-made peptide of nine amino acids modelled on gonadotropin-releasing hormone (GnRH, also called LH-RH). The label states that it is more potent than the natural hormone.1

Drugs@FDA lists many leuprolide applications, including Lupron (1985), Lupron Depot (1989), Lupron Depot-Ped (1993), Eligard (2002) and Fensolvi (2020).2,3,4,5,6

How does leuprolide work?

The label states that leuprolide acts as an inhibitor of gonadotropin secretion: after an initial stimulation, continued exposure suppresses the production of sex hormones by the ovaries and testes.1

The label states that this effect was reversible when the drug was stopped in animal studies, and that in men testosterone first rises before falling.1

What do human studies show?

The label describes a controlled study comparing leuprolide with diethylstilbestrol (DES), an older hormone treatment, in advanced prostate cancer. Survival after two years and objective response were comparable between the groups.1

In the HERO trial, 930 men with advanced prostate cancer received either a comparator drug, relugolix, or leuprolide for 48 weeks. Sustained testosterone suppression was reported in 88.8% of the leuprolide group and 96.7% of the relugolix group.8

HERO measured testosterone levels, not survival, so it does not show a difference in cancer outcomes between the two treatments.8

What the evidence base contains

  • Controlled human trial A controlled study, described in the label, comparing leuprolide with diethylstilbestrol (DES) in advanced prostate cancer, in which survival after two years was comparable.1
  • Large randomized human trial HERO: a randomized Phase 3 trial in 930 adults (men with advanced prostate cancer) who received treatment, 308 of them leuprolide, with sustained testosterone suppression as the main outcome. Leuprolide was the comparison treatment.8

Evidence-strength label: Large randomized human trials. How this label is assigned

Is leuprolide FDA-approved?

Yes. Drugs@FDA lists Lupron, application NDA019010, with an original approval date of April 9, 1985, followed by Lupron Depot on January 26, 1989, Lupron Depot-Ped on April 16, 1993, Eligard on January 23, 2002 and Fensolvi on May 1, 2020.2,3,4,5,6

The generic leuprolide label cited here (DailyMed SPL version 10, published July 6, 2026) states that it is indicated for the palliative treatment of advanced prostate cancer. Other leuprolide products carry their own labels and uses.1

That label has no boxed warning. It states that leuprolide is contraindicated in people allergic to GnRH, GnRH agonists or the product’s other ingredients.1

Its warnings cover a temporary worsening of prostate cancer symptoms when testosterone first rises, including cases of urinary blockage and spinal cord compression, possible harm to a fetus, severe skin reactions, high blood sugar and diabetes, heart attack, sudden cardiac death and stroke reported with GnRH agonists in men, and changes in heart rhythm.1

On August 26, 2026, FDA approved Vobrig (leuprolide acetate), from Sun Pharmaceutical Industries, for the treatment of central precocious puberty in children, according to the approval letter.7

Timeline

  1. FDA approves Lupron, the first leuprolide product, according to Drugs@FDA.2
  2. FDA approves Lupron Depot, according to Drugs@FDA.3
  3. FDA approves Eligard, according to Drugs@FDA.5
  4. Results of the HERO trial, with leuprolide as the comparison treatment, are published.8
  5. FDA approves Fensolvi, according to Drugs@FDA.6
  6. DailyMed publishes the leuprolide label version cited on this page.1
  7. FDA approves Vobrig for central precocious puberty in children.7

What is still unknown?

How the cited label’s findings apply to other leuprolide products, which have their own labels and approved uses.1,3,5

Whether the label’s comparison with DES reflects current treatment: the label does not give the study’s size or dates.1

Whether differences in testosterone suppression between leuprolide and newer treatments affect survival, which HERO did not measure.8

Sources for this version

  1. 1
    Leuprolide acetate kit · SPL version 10 · published 2026-07-06 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    Drugs@FDA application NDA019010 · original submission status AP · 1985-04-09 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    Drugs@FDA application NDA019732 · original submission status AP · 1989-01-26 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  4. 4
    Drugs@FDA application NDA020263 · original submission status AP · 1993-04-16 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application NDA021343 · original submission status AP · 2002-01-23 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Drugs@FDA application NDA213150 · original submission status AP · 2020-05-01 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  7. 7
    Vobrig (leuprolide acetate): NDA 213225 approval letter, August 26, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  8. 8
    Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer (HERO, 2020) · PMID 32469183 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026